Literature DB >> 12208980

The PPPY motif of human T-cell leukemia virus type 1 Gag protein is required early in the budding process.

Isabelle Le Blanc1, Marie-Christine Prévost, Marie-Christine Dokhélar, Arielle R Rosenberg.   

Abstract

Domains required late in the virus budding process (L domains) have been identified in the Gag proteins of a number of retroviruses. Here we show that the human T-cell leukemia virus type 1 candidate L domain motif PPPY is indeed required for virus production. Strikingly, however, mutation of this motif arrested virus particles at an earlier stage in the budding process than was seen for mutation of the L domain motifs thus far described for retroviruses. In view of the exchangeability of such domains, we propose that the retrovirus budding process may involve a continuum from bud formation to membrane fission.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12208980      PMCID: PMC136533          DOI: 10.1128/jvi.76.19.10024-10029.2002

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  40 in total

1.  Effect of mutations affecting the p6 gag protein on human immunodeficiency virus particle release.

Authors:  H G Göttlinger; T Dorfman; J G Sodroski; W A Haseltine
Journal:  Proc Natl Acad Sci U S A       Date:  1991-04-15       Impact factor: 11.205

Review 2.  Dynamic interactions of the Gag polyprotein.

Authors:  R C Craven; L J Parent
Journal:  Curr Top Microbiol Immunol       Date:  1996       Impact factor: 4.291

3.  Assembly and release of HIV-1 precursor Pr55gag virus-like particles from recombinant baculovirus-infected insect cells.

Authors:  D Gheysen; E Jacobs; F de Foresta; C Thiriart; M Francotte; D Thines; M De Wilde
Journal:  Cell       Date:  1989-10-06       Impact factor: 41.582

Review 4.  Examining the molecular genetics of HTLV-I with an infectious molecular clone of the virus and permissive cell culture systems.

Authors:  D Derse; J Mikovits; D Waters; S Brining; F Ruscetti
Journal:  J Acquir Immune Defic Syndr Hum Retrovirol       Date:  1996-05-01

5.  An assembly domain of the Rous sarcoma virus Gag protein required late in budding.

Authors:  J W Wills; C E Cameron; C B Wilson; Y Xiang; R P Bennett; J Leis
Journal:  J Virol       Date:  1994-10       Impact factor: 5.103

6.  Fine mapping and characterization of the Rous sarcoma virus Pr76gag late assembly domain.

Authors:  Y Xiang; C E Cameron; J W Wills; J Leis
Journal:  J Virol       Date:  1996-08       Impact factor: 5.103

7.  p6Gag is required for particle production from full-length human immunodeficiency virus type 1 molecular clones expressing protease.

Authors:  M Huang; J M Orenstein; M A Martin; E O Freed
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

8.  Positionally independent and exchangeable late budding functions of the Rous sarcoma virus and human immunodeficiency virus Gag proteins.

Authors:  L J Parent; R P Bennett; R C Craven; T D Nelle; N K Krishna; J B Bowzard; C B Wilson; B A Puffer; R C Montelaro; J W Wills
Journal:  J Virol       Date:  1995-09       Impact factor: 5.103

9.  The spacer peptide between human immunodeficiency virus capsid and nucleocapsid proteins is essential for ordered assembly and viral infectivity.

Authors:  H G Kräusslich; M Fäcke; A M Heuser; J Konvalinka; H Zentgraf
Journal:  J Virol       Date:  1995-06       Impact factor: 5.103

10.  The GAG precursor of simian immunodeficiency virus assembles into virus-like particles.

Authors:  M Delchambre; D Gheysen; D Thines; C Thiriart; E Jacobs; E Verdin; M Horth; A Burny; F Bex
Journal:  EMBO J       Date:  1989-09       Impact factor: 11.598

View more
  42 in total

1.  No strings attached: the ESCRT machinery in viral budding and cytokinesis.

Authors:  Bethan McDonald; Juan Martin-Serrano
Journal:  J Cell Sci       Date:  2009-07-01       Impact factor: 5.285

2.  The role of ITCH protein in human T-cell leukemia virus type 1 release.

Authors:  Batsukh Dorjbal; David Derse; Patricia Lloyd; Ferri Soheilian; Kunio Nagashima; Gisela Heidecker
Journal:  J Biol Chem       Date:  2011-07-01       Impact factor: 5.157

3.  Heterologous late-domain sequences have various abilities to promote budding of human immunodeficiency virus type 1.

Authors:  David E Ott; Lori V Coren; Tracy D Gagliardi; Kunio Nagashima
Journal:  J Virol       Date:  2005-07       Impact factor: 5.103

Review 4.  T-cell control by human T-cell leukemia/lymphoma virus type 1.

Authors:  Genoveffa Franchini; Risaku Fukumoto; Jake R Fullen
Journal:  Int J Hematol       Date:  2003-11       Impact factor: 2.490

5.  Basal budding and replication of the murine leukemia virus are independent of the gag L domains.

Authors:  Yosef Sabo; Nihay Laham-Karam; Eran Bacharach
Journal:  J Virol       Date:  2008-07-30       Impact factor: 5.103

6.  Role of the human T-cell leukemia virus type 1 PTAP motif in Gag targeting and particle release.

Authors:  Irene J Dorweiler; Susan J Ruone; Huating Wang; Richard W Burry; Louis M Mansky
Journal:  J Virol       Date:  2006-04       Impact factor: 5.103

7.  The Mason-Pfizer monkey virus PPPY and PSAP motifs both contribute to virus release.

Authors:  Eva Gottwein; Jochen Bodem; Barbara Müller; Ariane Schmechel; Hanswalter Zentgraf; Hans-Georg Kräusslich
Journal:  J Virol       Date:  2003-09       Impact factor: 5.103

8.  Functional hierarchy of two L domains in porcine endogenous retrovirus (PERV) that influence release and infectivity.

Authors:  Katherine T Marcucci; Yuri Martina; Frank Harrison; Carolyn A Wilson; Daniel R Salomon
Journal:  Virology       Date:  2008-03-19       Impact factor: 3.616

9.  Context-dependent effects of L domains and ubiquitination on viral budding.

Authors:  Juan Martin-Serrano; David Perez-Caballero; Paul D Bieniasz
Journal:  J Virol       Date:  2004-06       Impact factor: 5.103

10.  Both the PPPY and PTAP motifs are involved in human T-cell leukemia virus type 1 particle release.

Authors:  Huating Wang; Nicholas J Machesky; Louis M Mansky
Journal:  J Virol       Date:  2004-02       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.